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OBJECTIVES The goal of this study was to assess a new approach to stent the arterial duct in neonates with
a duct-dependent pulmonary circulation.
BACKGROUND Previous attempts to stent the neonatal arterial duct were unsatisfactory. Learning from these
failures, we speculated that covering the complete length of the duct with current low-profile
stents might avoid previous problems.
METHODS Ten neonates with duct-dependent pulmonary circulations through a short straight duct were
treated with stent implantation. The duct was crossed with an atraumatic 0.014-inch wire. A
low-profile premounted coronary stent (outer diameter 4F, length 13 to 24 mm, diameter
3.0 to 4.0 mm) was positioned within the duct, not protected by a sheath; care was taken to
cover the complete length of the duct from the aortaductal junction until well within the
pulmonary trunk.
RESULTS All stents could safely be deployed with adequate pulmonary flow at early- and medium-term
follow-up. There were no procedure-related complications; one patient died early from sepsis.
All patients had adequate relief of cyanosis for at least three to four months. During
follow-up, the pulmonary vasculature bed had grown without distortion. Acute occlusion of
a stented duct was not observed. Ductal flow progressively decreased slowly over several
months by luminal narrowing, until the stented duct had either become redundant or was
dilated/restented or until elective staged surgery was performed.
CONCLUSIONS With current technology, complete stenting of a short straight duct is a safe and effective
palliation, allowing adequate growth of the pulmonary arteries. (J Am Coll Cardiol 2004;
43:107–12) © 2004 by the American College of Cardiology Foundation
It has long been realized that patients with a duct-
dependent pulmonary circulation would benefit if duct
patency could be maintained reliably for several months
(1,2). Conventional palliative treatment in neonates with
such a duct-dependent circulation currently consists of
treatment with prostaglandin E1 for some days, followed by
the surgical creation of an aortopulmonary shunt if early
repair is not feasible. Shunt-related complications such as
chylothorax, phrenic and vagal nerve palsy, early or late
shunt occlusion or stenosis, distortion, and differential
growth of the pulmonary arteries (PAs) as well as surgical
adhesions are well-recognized and may add to the complex-
ity of subsequent surgeries (3–5).
Today, many vascular lesions are treated percutaneously,
and endovascular techniques can be extended to this clinical
setting. However, because of technical difficulties and un-
predictable outcomes, several previous investigators have
cautioned against routine placement of such stents in
neonates with duct-dependent pulmonary blood flow (PBF)
(6,7). Previous attempts to stent the neonatal duct with early
generation, rigid, bare stents using relatively bulky, stiff
wires, balloons, and sheaths frequently resulted in compli-
cations such as worsening cyanosis, bleeding, vessel rupture,
duct spasm, tissue prolapse, or acute thrombosis. Addition-
ally, incomplete covering of the duct frequently resulted in
duct constriction, with inadequate pulmonary flow within
hours or days after implantation. Learning from these
failures, we speculated that covering the complete length of
the duct with current low-profile, flexible, premounted
stents with good scaffolding might avoid such problems.
This report describes the experience from two university
pediatric cardiac centers over a two-year period with stent-
ing of the arterial duct in duct-dependent PBF.
METHODS
Patients. Between March 2001 and November 2002, stent
implantation of the arterial duct was attempted in 10
neonates and infants with duct-dependent pulmonary cir-
culation in two centers (University Hospital Leuven, Bel-
gium, and the Hospital for Sick Children, University of
Toronto, Canada). The procedure was offered as an alter-
native to surgical palliation after parental informed consent
was obtained. Only patients with a short and straight duct
were considered for this study; patients with a long and
tortuous duct, as typically seen with pulmonary atresia and
ventricular septal defect, were excluded. Early in the expe-
rience, the procedure was offered only to patients who
carried a high surgical risk (premature infant, single lung) or
whose pulmonary circulation was not completely duct-
From the *Paediatric Cardiology, University Hospitals, Leuven, Belgium; and the
†Hospital for Sick Children, University of Toronto, Toronto, Canada. This research
was sponsored in part by a grant from the Belgian Foundation for Research in
Paediatric Cardiology and the Victor Dielesen Research Grant.
Manuscript received February 1, 2003; revised manuscript received May 19, 2003,
accepted August 5, 2003.
Journal of the American College of Cardiology Vol. 43, No. 1, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.08.029
dependent. As experience grew, the procedure was offered
to all patients fulfilling the morphologic criteria for stent
implantation. All procedures were performed in agreement
with the ethical guidelines of each participating center.
The age of the patients ranged between one and 42 days,
median 6 days (Table 1). The body weight ranged from 2.5
to 3.7 kg, median 3.3 kg. The underlying pathology in the
10 patients was as follows: 3 had pulmonary valve atresia
and intact ventricular septum, 5 had critical pulmonary valve
stenosis with a hypoplastic right ventricle (1 in association
with double inlet left ventricle and subvalvular pulmonary
stenosis), and 2 patients had isolated PAs (1 in association
with tetralogy of Fallot, right aortic arch, and left arterial
duct to the left PA, and one patient with normal intracar-
diac anatomy, left aortic arch, and bilateral arterial ducts,
with isolation of the right PA).
Cardiac catheterization and stent implantation. The ini-
tial interventional therapy in 7 of 10 patients consisted of:
radiofrequency perforation and balloon dilation of pulmo-
nary atresia in three patients and balloon dilation only of
critical pulmonary valve stenosis in 4 patients. This was
done on the same day in three patients, and 2, 5, 11, and 33
days before stent implantation in four patients (allowing
assessment of the possibility of the pulmonary circulation
not being duct-dependent). In two patients with excluded
single PA and in the patient with complex univentricular
heart, there was no additional procedure but implantation of
the stent. The procedure was performed under general
anesthesia in all patients. Angiography (typically in profile
or perpendicular to the arch of the duct) was performed to
demonstrate the anatomy of the arterial duct, of which the
median length was 17 mm (range, 12 to 20 mm) (Fig. 1).
Stent implantation was performed from the femoral vein
in eight patients (in most patients through a 5F right
coronary guiding sheath) and from the femoral artery in two
patients (4F sheaths). After crossing the duct with a
0.014-inch guidewire, the infusion of prostaglandin was
discontinued to promote duct constriction; in patients
without previous ductal constriction, prostaglandin infusion
was stopped 6 h before the procedure. The duct was not
crossed with a sheath; a transvenous right coronary guiding
catheter ensured stability and allowed contrast flushes for
accurate positioning.
Coronary stents with good scaffolding properties, pre-
mounted on low-profile balloon dilation catheters were
used: Multi-link Tetra/Penta stents (Guidant, Santa Clara,
California) in six patients, Express Monorail (Boston Sci-
entific, Maple Grove, Minnesota) in two patients, and a
Coroflex (B Braun Medical, Emmenbruche, Switzerland)
and a Tristar stent (Guidant, Santa Clara, California) each
in one patient. The mean stent diameter was 3.8 mm (range,
3.0 to 4.0 mm). We aimed to stent the complete length of
the duct with a single stent. Stent length was chosen slightly
longer than the duct length. When positioning the stent,
care was taken to align the superior aortic end of the stent
with the cranial aortoductal junction, avoiding any protru-
sion into the aorta; the stent therefore would protrude
slightly into the pulmonary trunk (Fig. 2). We aimed not to
reach the zenith of the main PA, because this may cause
erosion or perforation.
After stent implantation, repeat angiography was per-
formed to confirm the stent position and to exclude incom-
plete stenting of the duct (Fig. 3). In case of incomplete
stenting, an additional stent was implanted to cover the
whole duct.
Prophylactic antibiotic treatment (cefazolin in most pa-
tients) was given for 24 h.
During follow-up, nine patients were on antiplatelet
agents (1 to 3 mg/kg acetylsalicylic acid alone in eight
patients, and in combination with low-molecular-weight
heparin and clopidogrel in one patient). One patient re-
ceived low-molecular-weight heparin alone for two weeks.
RESULTS
In the 10 patients, a total of 13 stents were successfully
implanted; a single stent was required in seven patients, and
two stents were implanted in two patients at the initial
procedure. In Patient 3, two procedures were required on
consecutive days: the first stent covered the duct except 3
mm at the aortic end, which was widely open at that time;
within 20 h the aortic end showed significant duct constric-
tion, which was relieved by a second stent. The results are
summarized in Table 1. The median fluoroscopy time was
28 min (range, 9 to 58 min) including the primary proce-
dure when done in a single session.
The mean length of the final stent (either single stent or
combination of two stents) for this group was 19 mm
(range, 13 to 24 mm). There were no deaths directly related
to the procedure. One patient died four days after implan-
tation due to E. coli septicemia, where, in retrospect, the
septic episode may have begun before the procedure. At
autopsy, the stent was widely patent. Three patients (all
with stent diameter of 4.0 mm) initially required antifailure
treatment due to increased PBF. Repeat cardiac catheter-
ization was performed in seven patients 4.7 months after
implantation (range, 1.4 to 9.1 months). In all of these
patients, adequate growth of the PAs was observed without
distortion. Luminal narrowing within the duct had resulted
in a significant reduction of the inner diameter in most
patients. The aortic lumen was not affected by any implant.
In Patient 1, the duct was restented 4.7 months after
implantation with a 4-mm stent with a good clinical result.
A bidirectional cavopulmonary shunt was subsequently
performed in two patients, and is scheduled in another
patient. Patients 5 and 8 underwent elective unifocalization
of the PAs at 3.9 and 2.3 months; both stents were widely
Abbreviations and Acronyms
PA  pulmonary artery
PBF  pulmonary blood flow
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Table 1. Patient Characteristics, Stent Data, and Clinical Outcome
Patient Diagnosis
Age,
days
Weight,
kg
Duct
Length,
mm Lungs
Stent
Length,
mm
Stent
Diameter,
mm Immediate Result
FU
Months
Reintervention/
Last Echocardiography at FU
1 PA-IVS, TS 35 3.3 18 2 20 (18 & 9) 4.0 Generous flow, mild
decompensation
7.5 Restent 4 mm/18 mm after
4.7 months; then CPS at
7.5 months
2 Critical PS 1 2.8 12 2 13 3.5 Adequate flow, no decompensation 7.7 Spontaneous occlusion stent, no
residual PS, PFO bidirectional
shunt
3 PA-IVS, TS 4 3.2 18 2 22 (18 & 13) 4.0 Adequate flow, mild
decompensation
6.2 CPS shunt, RV overhaul at
6.2 months
4 Critical PS 6 3.7 17 2 18 3.5 Adequate flow, no decompensation 14.7 Small residual ductal shunt,
clinically no cyanosis
5 TOF, excluded left PA 42 3.6 15 1 18 4.0 Adequate flow, no decompensation 3.9 Repair TOF with unifocalization
at 3.9 months
6 UVH, DILV, sub PS
& PS
7 3.4 14 2 18 4.0 Adequate flow, slight protrusion of
stent in Ao
0.1 Patient died 4 days after stenting
(E coli sepsis)
7 PA-IVS, TS 2 3.5 20 2 24 4.0 Adequate flow, moderate
decompensation
9.1 Adequate ductal flow, scheduled
for RV overhaul
8 Excluded right PA 3 2.6 14 1 15 3.0 Generous flow, transient reperfusion
edema
2.3 Implantation RAP into
pulmonary trunk at 2.3
months
9 Critical PS 6 2.5 18 2 22 (18 & 13) 3.0 Adequate flow, no decompensation 4.6 Adequate growth RV, duct
spontaneously closed
10 Critical PS, TS 12 2.5 16 2 20 3.0 Adequate flow, no decompensation 5.2 Adequate growth RV, duct
redundant 3 months
Median 6.0 3.3 17 5.7
Ao  aorta; CPS  cavo pulmonary shunt; DILV  double inlet left ventricle; FU  follow-up; IVS  interventricular septum; PA  pulmonary artery; PA-IVS  pulmonary atresia-intact ventricular septum; PFO  patent foramen
ovale; PS  pulmonary valve stenosis; RAP  right pulmonary artery; RV  right ventricle; TOF  tetralogy of Fallot; TS  tricuspid stenosis; UVH  univentricular heart.
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patent at the time of surgery. There were no technical
problems caused by the stents during the subsequent sur-
geries, and the stents could easily be occluded completely by
simple external compression (no recoil).
Adequate right ventricular growth had occurred in four
patients, making the stented ducts redundant; medication
was stopped, leaving the stents to occlude spontaneously.
Spontaneous ductal occlusion was documented echocardio-
graphically in two patients 4.6 and 7.7 months after stent
implantation; minimal duct flow persisted in the two re-
maining patients 5.2 and 14.7 months after stenting.
DISCUSSION
Several authors have highlighted technical difficulties en-
countered when stenting the arterial duct in duct-dependent
cyanotic congenital heart disease (8–10). However, im-
proved materials resulted in broadened indications for per-
cutaneous intraluminal techniques, whereby many of the
technical difficulties encountered in the past now can be
avoided.
Current technique. Long, flexible stents, premounted on
low-profile balloons are used. When choosing a stent,
important features are stent length, diameter, and design.
STENT LENGTH. The most distal parts of the duct appear to
have a remarkable power to constrict even when only a few
millimeters are left unsupported (9). Previous animal studies
revealed that placement just proximal to the duct orifice
resulted in an intimal process that eventually led to complete
closure within days of implantation (11). Therefore, great
care must be taken to cover the duct completely from the
aortic end until well within the pulmonary trunk. The stent
Figure 1. Angiogram (profile) in pulmonary artery through the 5F right
coronary guiding sheath. Duct constriction at the pulmonary end is clearly
seen; the aortic end of the duct is wide open.
Figure 2. Schematic representation of stent sizing and positioning. (A)
The stent should stretch from the cranial aortoductal junction (point A),
until halfway to the ductal constriction and the zenith of the ductal arch
(point B). (B) When positioning and deploying the stent, the distal end of
the stent should be aligned with point A without protrusion in the aorta;
the proximal end of the stent will then protrude into the pulmonary trunk.
Figure 3. Cine-frames showing positioning of the stent (A) and final stent
position after deployment (B). The radio-opaque gastric tube is very useful
as reference.
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length is, thus, chosen slightly longer than the length of the
duct.
STENT DIAMETER. Surgeons use a 4- or 5-mm interposi-
tion tube when creating a modified Blalock-Taussig shunt
in neonates; however, the restriction of these shunts early
after creation lies within the orifice of the subclavian artery.
A stented duct is more comparable with a central shunt,
which has no restriction at the aortic end; surgeons prefer in
neonates for such shunts conduits from 3 up to 4 mm. The
final lumen within the stent, however, will depend on the
stent diameter at implantation, which will decrease within
hours-days by contraction of the vessel wall leading to tissue
prolapse through the stent struts, and later on will further
decrease by endothelial hyperplasia. Table 1 shows the
immediate result in function of stent diameter, patient
weight, and single or double lung perfusion. All neonates
with stent diameters of 4.0 mm initially had excessive
pulmonary flow.
STENT CHARACTERISTICS. The stent design and material
determine cross-sectional area, strut thickness, and radial
force. Larger metallic cross-sectional areas, thicker struts,
and smaller cell-areas result in good scaffolding with limited
tissue prolapse, which is important when used in the arterial
duct. However, these properties reduce the flexibility and
conformability of the stent, and are known to enhance
in-stent restenosis rate in coronary arteries. Radial force and
side-branch accessibility are no issue for a stent deployed in
the arterial duct.
Schneider et al. (11) observed, within days after implan-
tation, significant stenosis within a gap articulation in the
Palmaz-Schatz coronary stent; this was treated with an
additional stent across the articulation. In patients with a
tortuous duct, we attempted to stent with flexible stents
with more conformability to follow the curves; however,
stents with a larger cell area allow significant tissue prolapse,
with a restrictive cobblestone appearance within hours in
some cases. For the short straight duct in the patient group
reported in this study, we chose stents with small cell area
and good scaffolding; the somewhat reduced flexibility
caused no problem when positioning these stents, and
conformability is not required for this type of duct.
DUCT AND PROSTAGLANDIN. In order to grip the stent at
deployment, some ductal constriction is required. If the duct
has not constricted since birth, as typical in patients with
fetal or very early neonatal presentations, where prostaglan-
dins are started very early, this medication should be
stopped several hours (e.g., 6 h) before the procedure. In
patients presenting after duct constriction with cyanosis,
prostaglandins can be stopped at the beginning of the
procedure, or after the duct has been crossed with the
guiding wire. Enhanced constriction during the procedure
can be obtained by administering intravenous indomethacin
or ibuprofen.
ANTICOAGULATION AND ANTIAGGREGATION. It is difficult
to determine the role of anticoagulant and antiplatelet
drugs. During the procedure, standard heparin should be
given. We currently do not neutralize the heparin at the end
of the procedure, but acetylsalicylic acid 1 to 3 mg/kg/day is
started for as long as stent patency is required. The value of
clopidogrel needs to be determined.
With growing confidence in the technique, patients are
now considered for hospital discharge within 48 h after
implant, provided there is no other indication for a pro-
longed stay.
Neointimal proliferation. Duct patency after stenting is
limited by in-stent restenosis, which occurs due to neointi-
mal proliferation and/or peal formation (8,11). The ideal
stent for this procedure still needs to be defined. Stent
design determines (non-)metal surface area, radial force,
flexibility, conformability, scaffolding, and prevention of
tissue prolapse. Drug-eluting stents or covered stents have
been proposed as a means of preventing in-stent restenosis
in adults (12,13). Covered stents are slightly more bulky and
require larger introducer sheaths (currently 1 to 2F sizes).
The drug-eluting coatings contain agents that inhibit
thrombus formation (e.g., heparin), inflammation (e.g.,
dexamethasone), and cellular proliferation (e.g., sirolimus or
paclitaxel) (14). Stents eluting antimitotic agents such as
sirolimus and paclitaxel show the most promising results in
coronary artery disease, with significant inhibitory effects on
neointimal hyperplasia. Studies to evaluate the efficacy and
safety of duct stenting with such coated stents in newborn
animals will be initiated in the near future. This promising
development in stent technology may prolong the duration
of duct patency, rendering it an even more attractive
alternative to a surgical shunt. On the other hand, in-stent
stenosis can be managed by redilating or restenting the
implant as a function of patient growth and/or intimal
proliferation.
Comparison with the gold-standard: the surgical shunt.
This enhanced technology obviously needs to be compared
with the standard surgical shunt. While the stented arterial
duct obviously will provide only temporary augmented
pulmonary flow, as with any aortopulmonary shunt, we have
been impressed by the fast recovery of the patients after
stent implantation, much faster than with any surgery. The
procedure is well-tolerated, even in the premature and small
infants, who constitute a subgroup with higher operative
risks. Without stent implantation, such premature infants
would require prolonged prostinoid infusions, allowing the
surgeon to operate on a larger child with more limited
morbidity. In this small series, the stent strategy appears to
be more cost-effective.
The lumen of a stented duct appears to narrow faster than
a surgical shunt; however, all stented ducts gave adequate
pulmonary flow for several months. There were no acute
stent occlusions. If required, the stented duct can be
redilated, which allows titration of pulmonary flow to
patient size. Such redilation-restenting must be considered
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when assessing cost-effectiveness of each strategy (15).
Nevertheless, based on this early experience and these
considerations, stent implantation has now become our
treatment of choice for the short, straight duct.
Conclusions. With the current technology, stenting the
arterial duct in selected patients with duct-dependent pul-
monary circulation is a safe and efficient alternative to a
surgical shunt.
Compared with primary surgery, this approach is less
invasive and offers the possibility of adapting to clinical
needs in the individual patient. Compared with long-term
prostaglandin infusions, early duct stenting significantly
shortens hospitalization and reduces treatment costs. In our
series, no acute thrombosis of the stented duct occurred,
only slow progressive luminal narrowing. The ability to
influence and optimize the stent size by repeat balloon
dilation or restenting during follow-up is an additional
advantage of this approach, allowing for patient growth.
The stented arterial duct fulfills its function as a surrogate
for an aortopulmonary shunt, augmenting the PBF until a
definitive surgical procedure can be performed or until the
duct flow becomes redundant. Future research should be
directed towards improved stent design for more complex
tortuous ducts.
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